NRD
RMD icon

Nebula Research & Development’s ResMed RMD Stock Holding History

Nebula Research & Development’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,935
Closed -$1.79M – 705
2025
Q2 		$1.79M Sell
6,935
-7,371
-52% -$1.76M 0.15% 218
2025
Q1 		$3.2M Buy
14,306
+11,978
+515% +$2.8M 0.3% 70
2024
Q4 		$532K Buy
+2,328
New +$561K 0.06% 529
2024
Q2 		– Sell
-1,908
Closed -$378K – 1012
2024
Q1 		$378K Buy
+1,908
New +$350K 0.08% 449
2023
Q3 		– Sell
-2,870
Closed -$627K – 639
2023
Q2 		$627K Buy
+2,870
New +$640K 0.48% 55

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Nebula Research & Development's RMD Position: Q3 2025 in Review

Nebula Research & Development sold out of ResMed (RMD) in Q3 2025, closing a stake of 6,935 shares — an estimated $1.79M sold.

Nebula Research & Development first reported a position in RMD in Q2 2023 and held it in 5 quarters. The position peaked at $3.2M in Q1 2025. 949 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

  • Nebula Research & Development reported no remaining ResMed position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 6,935 ResMed shares in Q3 2025, an estimated $1.79M.
  • Nebula Research & Development first reported a position in ResMed in Q2 2023 and held it in 5 quarters.
  • Nebula Research & Development's ResMed position peaked at $3.2M in Q1 2025.
  • 949 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.